正在接受替诺福韦和去羟肌苷治疗的临床稳定、有治疗经验的成年人。
Clinically stable treatment-experienced adults receiving tenofovir and didanosine.
作者信息
Di Biagio Antonio, Beltrame Andrea, Cenderello Giovanni, Ferrea Giuseppe, De Maria Andrea
机构信息
Department of Infectious Diseases, University of Genova, Genova, Italy.
出版信息
HIV Clin Trials. 2006 Jan-Feb;7(1):10-5. doi: 10.1310/0B0R-J1LP-KQPF-43HB.
METHOD
Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine.
RESULTS
Patients treated with TDF and ddI do not have a higher risk of early immunological or virological failure.
CONCLUSION
Treatment success and increase in CD4+ lymphocytes may depend, among other factors, on historical CD4+ nadir. These data agree with previous work and argue against preemptive switches for fear of side effects or immunological/virological failure away from a successful ddI-TDF combination in clinically stable drug-experienced patients.
方法
对有药物治疗史的患者进行24周治疗，分析接受去羟肌苷（ddI）和替诺福韦（TDF）加蛋白酶抑制剂（PI）或非核苷类逆转录酶抑制剂（NNRTI）治疗的患者（17例）的病毒学、免疫学和临床数据，并与接受ddI加拉米夫定治疗的14例患者以及接受ddI加司他夫定治疗的19例患者进行比较。
结果
接受TDF和ddI治疗的患者早期免疫或病毒学失败风险并不更高。
结论
治疗成功和CD4 +淋巴细胞增加可能取决于多种因素，包括既往CD4 +最低点。这些数据与之前的研究一致，反对因担心副作用或免疫/病毒学失败而在临床稳定的有药物治疗史患者中，从成功的ddI-TDF联合治疗方案进行预防性换药。
Zotero 插件